• Je něco špatně v tomto záznamu ?

Long-term medical management of uterine fibroids with ulipristal acetate

J. Donnez, O. Donnez, D. Matule, HJ. Ahrendt, R. Hudecek, J. Zatik, Z. Kasilovskiene, MC. Dumitrascu, H. Fernandez, DH. Barlow, P. Bouchard, BC. Fauser, E. Bestel, E. Loumaye,

. 2016 ; 105 (1) : 165-173.e4. [pub] 20151023

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16020211

OBJECTIVE: To investigate the efficacy and safety of repeated 12-week courses of 5 or 10 mg daily ulipristal acetate for intermittent treatment of symptomatic uterine fibroids. DESIGN: Double-blind, randomized administration of four 12-week courses of ulipristal acetate. SETTING: Gynecology centers. PATIENT(S): Four hundred fifty-one subjects with symptomatic uterine fibroid(s) and heavy menstrual bleeding. INTERVENTION(S): Four repeated 12-week treatment courses of daily 5 or 10 mg ulipristal acetate. MAIN OUTCOME MEASURE(S): Endometrial safety and general safety, laboratory parameters, amenorrhea, controlled bleeding, fibroid volume, quality of life (QoL), and pain. RESULT(S): Efficacy results, such as bleeding control and fibroid volume reduction, were in line with previously published data. Pain and QoL showed marked improvements from screening, even during the off-treatment intervals. The safety profile of ulipristal acetate was confirmed, and repeated treatment courses did not increase the occurrence of adverse reactions. There were no significant changes in laboratory parameters during the study. The percentage of subjects with endometrial thickness ≥ 16 mm was 7.4% (all subjects) after the first treatment course and returned to below screening levels (4.9%) in subsequent treatment courses. As in previous studies, ulipristal acetate did not increase the occurrence of endometrial features of concern. The frequency of nonphysiological changes did not increase with repeated treatment. They were observed in 17.8% and 13.3% of biopsies after treatment courses 2 and 4, respectively, and were reversible after treatment cessation. CONCLUSION(S): The results of this study demonstrate the efficacy and further support the safety profile of repeated intermittent treatment of symptomatic fibroids with ulipristal acetate. CLINICAL TRIAL REGISTRATION NUMBER: NCT01629563.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020211
003      
CZ-PrNML
005      
20160727105414.0
007      
ta
008      
160722s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.fertnstert.2015.09.032 $2 doi
024    7_
$a 10.1016/j.fertnstert.2015.09.032 $2 doi
035    __
$a (PubMed)26477496
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Donnez, Jacques $u Société de Recherche pour l'Infertilité, Brussels, Belgium. Electronic address: jacques.donnez@gmail.com.
245    10
$a Long-term medical management of uterine fibroids with ulipristal acetate / $c J. Donnez, O. Donnez, D. Matule, HJ. Ahrendt, R. Hudecek, J. Zatik, Z. Kasilovskiene, MC. Dumitrascu, H. Fernandez, DH. Barlow, P. Bouchard, BC. Fauser, E. Bestel, E. Loumaye,
520    9_
$a OBJECTIVE: To investigate the efficacy and safety of repeated 12-week courses of 5 or 10 mg daily ulipristal acetate for intermittent treatment of symptomatic uterine fibroids. DESIGN: Double-blind, randomized administration of four 12-week courses of ulipristal acetate. SETTING: Gynecology centers. PATIENT(S): Four hundred fifty-one subjects with symptomatic uterine fibroid(s) and heavy menstrual bleeding. INTERVENTION(S): Four repeated 12-week treatment courses of daily 5 or 10 mg ulipristal acetate. MAIN OUTCOME MEASURE(S): Endometrial safety and general safety, laboratory parameters, amenorrhea, controlled bleeding, fibroid volume, quality of life (QoL), and pain. RESULT(S): Efficacy results, such as bleeding control and fibroid volume reduction, were in line with previously published data. Pain and QoL showed marked improvements from screening, even during the off-treatment intervals. The safety profile of ulipristal acetate was confirmed, and repeated treatment courses did not increase the occurrence of adverse reactions. There were no significant changes in laboratory parameters during the study. The percentage of subjects with endometrial thickness ≥ 16 mm was 7.4% (all subjects) after the first treatment course and returned to below screening levels (4.9%) in subsequent treatment courses. As in previous studies, ulipristal acetate did not increase the occurrence of endometrial features of concern. The frequency of nonphysiological changes did not increase with repeated treatment. They were observed in 17.8% and 13.3% of biopsies after treatment courses 2 and 4, respectively, and were reversible after treatment cessation. CONCLUSION(S): The results of this study demonstrate the efficacy and further support the safety profile of repeated intermittent treatment of symptomatic fibroids with ulipristal acetate. CLINICAL TRIAL REGISTRATION NUMBER: NCT01629563.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a protinádorové látky $x aplikace a dávkování $x škodlivé účinky $7 D000970
650    _2
$a biopsie $7 D001706
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a leiomyom $x komplikace $x diagnóza $x farmakoterapie $7 D007889
650    _2
$a lidé středního věku $7 D008875
650    _2
$a norpregnadieny $x aplikace a dávkování $x škodlivé účinky $7 D009649
650    _2
$a měření bolesti $7 D010147
650    _2
$a pánevní bolest $x diagnóza $x farmakoterapie $x etiologie $7 D017699
650    _2
$a kvalita života $7 D011788
650    _2
$a průzkumy a dotazníky $7 D011795
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a děložní krvácení $x diagnóza $x farmakoterapie $x etiologie $7 D014592
650    _2
$a nádory dělohy $x komplikace $x diagnóza $x farmakoterapie $7 D014594
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Evropa $7 D005060
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Donnez, Olivier $u Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.
700    1_
$a Matule, Dace $u Medical Company ARS Gynaecology Department No. 5, Riga, Latvia.
700    1_
$a Ahrendt, Hans-Joachim $u Praxis für Frauenheilkunde, Klinische Forschung und Weiterbildung, Magdeburg, Germany. $7 gn_A_00002536
700    1_
$a Hudecek, Robert $u Department of Obstetrics and Gynaecology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
700    1_
$a Zatik, Janos $u Szent Anna Szuleszeti, Nogyogyaszati es Ultrahang Maganrendelo, Debrecen, Hungary.
700    1_
$a Kasilovskiene, Zaneta $u Private Clinic Maxmeda, Vilnius, Lithuania.
700    1_
$a Dumitrascu, Mihai Cristian $u Centrul Medical EUROMED SRL, Obstetrica-Ginecologie, Bucuresti, Romania.
700    1_
$a Fernandez, Hervé $u Hôpital Bicêtre-APHP, Service de Gynécologie-Obstétrique, Le Kremlin-Bicêtre, France.
700    1_
$a Barlow, David H $u Hamad Medical Corporation, Qatar and University of Glasgow, Glasgow, United Kingdom.
700    1_
$a Bouchard, Philippe $u Service d'Endocrinologie, Hôpital Saint-Antoine, Paris, France.
700    1_
$a Fauser, Bart C J M $u Department of Reproductive Medicine and Gynecology, University Medical Center Utrecht, Utrecht, the Netherlands.
700    1_
$a Bestel, Elke $u PregLem S.A., Plan-les-Ouates, Geneva, Switzerland.
700    1_
$a Loumaye, Ernest $u ObsEva S.A, Plan-Les-Ouates, Geneva, Switzerland.
773    0_
$w MED00001795 $t Fertility and sterility $x 1556-5653 $g Roč. 105, č. 1 (2016), s. 165-173.e4
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26477496 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160727105635 $b ABA008
999    __
$a ok $b bmc $g 1154881 $s 944739
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 105 $c 1 $d 165-173.e4 $e 20151023 $i 1556-5653 $m Fertility and sterility $n Fertil Steril $x MED00001795
LZP    __
$a Pubmed-20160722

Najít záznam

Citační ukazatele

Možnosti archivace